Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%
Market cap
$64.0B
P/E
17.9×
Fwd P/E
17.8×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
17.21 26.15 48.65 51.66

+8 more quarters

P/S ratio
2.99 4.52 7.03 7.48
P/FCF ratio
17.31 26.81 38.59 37.83
P/Operating CF
42.57 267.75 103.49 107.71
P/B ratio
2.49 3.57 5.77 6.12
EV/Sales
3.56 4.98 7.50 8.01
EV/EBITDA
13.46 19.65 29.97 31.16
EV/FCF
20.64 29.57 41.18 40.53
Current Ratio
1.24 1.90 1.62 1.51
Net Debt/EBITDA
7.88 6.60 7.97 7.43
Debt/Equity
0.50 0.42 0.47 0.49
Earnings Yield
5.81% 3.82% 2.06% 1.94%
Free Cash Flow Yield
5.78% 3.73% 2.59% 2.64%
Free Cash Flow per Share
0.87 0.12 0.68 0.78
Book value per Share
17.12 17.58 16.53 15.95
Free Cash Flow
1,279.00 171.00 1,013.00 1,162.00
EV/EBIT
18.04 27.12 41.70 44.70
Other line items

Show all line items

Columns are period end dates